Citius Oncology, Inc. Reports Fiscal First Quarter 2025 Financial Results and Provides Business Update
Citius Oncology, Inc. (“Citius Oncology” or the “Company”) (Nasdaq: CTOR), a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal first quarter ended December 31, 2024. https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.jpg Fiscal First Quarter 2025 Business Highlights and Subsequent Developments — Engaged Jefferies as exclusive […]